

1 TO EVALUATE OUTCOME AND COMPLICATIONS BETWEEN SUPERVISED AND
2 UNSUPERVISED MEDICAL ABORTION PILL INTAKE
3

4 **ABSTRACT**

5 **Introduction**

6 Due to the easy access of medical abortion pill over the counter without medical
7 consultation and despite guidelines and medical termination of pregnancy act, there
8 is an increase in incidence of unsafe abortion, often leading to serious health
9 complications.

10 **Objective**

11 To evaluate outcome and complications, socio-demographic factors that lead women
12 to self administration of medical abortion pills and to assess awareness regarding
13 use of medical abortion pills between supervised and unsupervised intake of medical
14 abortion pills.

15 **Methods**

16 This prospective observational study was conducted between from June 2022 - June
17 2024, where a total of 600 patients were enrolled in the study. Patients were divided
18 into two groups in which one group had supervised intake of MTP pills and other
19 group had unsupervised intake of MTP pills. Their socio-demographic profile,
20 indication of intake of MTP pill, source of drug, awareness about MTP pill or any
21 other form of contraceptions, outcome and complications were evaluated. The data
22 were encoded and entered into MS Excel spreadsheet application. Analysis was
23 done using Origin pro software. Statistical analysis was done to analyse between the
24 groups using percentage and Chi square test on categorical variables. The

25 correlation between dependent and independent variables was evaluated using
26 multivariate logistic regression.

27

28 **Result**

29 In supervised group, majority (58.53%) were aged between 21-30 years of age,
30 whereas in unsupervised group majority(61.33%) were aged between 31-40 years of
31 age. It was observed that in both groups majority of patients belonged to middle
32 economic status. It had been observed that majority(90.66%) of pregnancy in
33 unsupervised group was diagnosed by UPT and with history of MTP pill intake
34 between 9-12 weeks gestation(43.34%) leading to more complications, while in
35 supervised intake, pregnancy was diagnosed by USG(99.66%)and termination of
36 pregnancy was done before 9 weeks of gestation(72.67%) with minimal
37 complications. Anaemia is the most common associated co-morbidity were severe
38 anaemia was noted in 25% patients in unsupervised group compared to 15% in
39 supervised group. In unsupervised group, 42.67% patients required suction and
40 evacuation with blood transfusion with only 14% in supervised group.

41 **Conclusion**

42 It was observed that the magnitude of complications was more seen in unsupervised
43 intake of MTP pill like need for blood transfusion, laparotomy, hysterectomy and
44 maternal mortality. There is an urgent need of restricting the free availability of over
45 the counter MTP pill and to educate and increase awareness about the
46 complications of unsupervised MTP pill intake.

47 **Keywords:** MTP pill; unsupervised intake; awareness; outcome; complications

48

49

50

51 **INTRODUCTION**

52 Unsafe abortion remains a critical global reproductive health issue, presenting
53 significant risks and often leading to severe, life-threatening complications. In India,
54 an estimated 6.4 million abortions occur annually, with 56% classified as unsafe.
55 These unsafe abortions contribute significantly to maternal mortality, accounting for
56 8-20% of all maternal deaths. ⁽¹⁾

57 In India, the All India Institute of Medical Sciences (AIIMS), in collaboration with the
58 Ministry of Health and Family Welfare, has developed guidelines for the use of
59 medical abortion pills. These guidelines recommend a combination pack of 1 tablet
60 of Mifepristone (200 mg) and 4 tablets of Misoprostol (200 mcg each) for terminating
61 pregnancies up to 63 days of gestation. According to the Medical Termination of
62 Pregnancy (MTP) Act, only registered medical practitioners are authorized to
63 prescribe these pills. ⁽²⁾

64 The MTP Act of 2021, effective from March 25, 2021, extends the permissible
65 gestational age for abortion to 24 weeks, up from the previous limit of 20 weeks.
66 Under the revised act, the opinion of one registered medical practitioner is required
67 for abortions up to 20 weeks, while two practitioners' opinions are needed for
68 abortions between 20-24 weeks. This contrasts with the previous requirement of one
69 practitioner's opinion for terminations up to 12 weeks and two practitioners' opinions
70 for terminations between 12-20 weeks. ⁽³⁾

71 WHO guidelines necessitate women requesting medical abortion to confirm
72 pregnancy, estimate gestational age and locate site of pregnancy, rule out
73 contraindications and it also recommends that the person or facility providing
74 Medical abortion should have back up facility in case of failed or incomplete
75 abortion.¹⁴ Unwanted pregnancies are a significant global challenge, leading to an

76 estimated 42 million induced abortions annually, with about 20 million of these being
77 unsafe⁽⁵⁾.

78 This study aims to evaluate the outcomes and complications of self-administered
79 medical abortion pills, comparing supervised and unsupervised settings in tertiary
80 care facilities. Health education should emphasize the importance of medical
81 counselling and supervision during abortions and the risks of self-medication. Strict
82 enforcement of restrictions on over-the-counter abortion pills is necessary, along with
83 increased awareness of contraception to reduce unwanted pregnancies.

84

85 **MATERIALS AND METHODS**

86 This Prospective observational study was conducted in Upper India Sugar
87 Exchange Maternity Hospital, GSVM Medical College, Kanpur, UP in the Department
88 of Obstetrics and Gynaecology spanning two years from June 2022 to June 2024 on
89 600 patients .This methodology was selected to evaluate outcome and complications
90 between supervised and unsupervised patients following MTP pill intake. All patients
91 visiting OPDs and IPDs with history of administration of medical abortion pills with
92 and without prescription were taken into study. By self administration we mean that
93 these pregnant women did not have any medical consultation with a registered
94 medical practitioner and took abortion pills which were purchased from the pharmacy
95 without any prescription either by self or by some close relative. Woman with any
96 history of surgical intervention or procedure after MTP pills intake were excluded
97 from study. The data were encoded and entered into MS Excel spreadsheet
98 application. Analysis was done using Origin pro software. Statistical analysis was
99 done to analyse between the groups using percentage and Chi square test on

100 categorical variables. The correlation between dependent and independent variables
101 was evaluated using multivariate logistic regression.

102 **Result:**

103 Table 1 presents the overall comparison of each variable between supervised and
104 unsupervised intake of medical abortion pill along with their contributory
105 percentages. In supervised group, majority (58.53%) were aged between 21-30
106 years of age, whereas in unsupervised group majority(61.33%) were aged between
107 31-40 years of age. It was observed that in both groups majority of patients belonged
108 to middle economic status. It had been observed that majority(90.66%) of pregnancy
109 in unsupervised group was diagnosed by UPT and with history of MTP pill intake
110 between 9-12 weeks gestation(43.34%), while in supervised intake, pregnancy was
111 diagnosed by USG(99.66%)and termination of pregnancy was done before 9 weeks
112 of gestation(72.67%).

113 Severe anaemia was noted in 25% patients in unsupervised group compared to 15%
114 in supervised group. In unsupervised group, 42.67% patients required suction and
115 evacuation with blood transfusion with only 14% in supervised group. Complications
116 such as shock (2.34%), sepsis (4.35%) and mortality (1.62%) had been reported in
117 this study compared to none in supervised group.

118 Table 2 presents the crude and adjusted ratio for study variables about intake of
119 medical abortion pill between supervised and unsupervised intake. The crude odds
120 ratio of complication after intake were higher in parity more than
121 3(COR:1.79,CI:1.14-2.71). However, multivariate logistic regression revealed that a
122 parity of more than 2(AOR:1.49,CI:1.21-1.71) were more likely of landing into
123 complications. The crude odds ratio of complication after intake were higher in period
124 of gestation of 9-12 weeks (COR:1.35,CI:1.10-1.58),when adjusted it was it was

125 observed that both period of gestation of >9weeks and 9-12 weeks revealed are
 126 equally likely for causing complications.(COR:1.14,CI 0.85-1.51).

127

128 Table1: Overall study variables were shown and distribution percentage was plotted
 129 for each variables. Comparison between the supervised and un-supervised was
 130 shown in the present table along with their contributory percentages.

Characteristics		Supervised (N)	%	Un supervised (N)	%	Chi square	P value
Age(years)	<20	38	12.8	32	10.67	7.7724	.050957
	21-30	175	58.53	78	26		
	31-40	85	28.43	184	61.33		
	>40	1	0.3	6	1.3		
Religion	Hindu	258	86.29	254	86.29	399.1824	< .00001
	Muslim	41	13.71	45	13.71		
Education	Literate	276	92.31	288	96.33	4.4906	.034081
	Illiterate	23	7.69	11	3.67		
Residence	Rural	18	6.02	14	4.68	0.5283	.467336
	Urban	281	93.98	285	95.32		
Marital Status	Married	17	5.68	16	5.35	0.0321	.857868
	Unmarried	282	94.32	283	94.65		
Economic Status	Upper	15	5.06	36	12.04	9.4535	.008855
	Middle	245	81.90	227	75.92		
	Low	39	13.04	36	12.04		
Medical History	Yes	285	95.32	298	99.66	11.5565	.000675
	No	14	4.68	1	0.34		
Parity	G1	50	16.72	32	10.70	138.5755	< 0.00001
	G2	239	79.94	138	46.16		
	G3	1	0.34	100	33.44		
	>4	9	3.00	29	9.70		
POG (weeks)	<9	218	72.67	85	28.33	1.5601	.458389

	9-12	67	22.33	130	43.34		
	>12	15	5	85	28.33		
Ascertainment of pregnancy(USG/UPT)	USG	298	99.66	28	9.34	89.1209	<.00001
	UPT	1	0.34	272	90.66		
No. of Pills	Complete	151	50.51	147	49.16	0.107	.743557
	In-complete	148	49.49	152	50.84		
No. of times pills were taken	Once	276	92.31	276	92.31	0	1
	Twice	23	7.69	23	7.69		
	Thrice	0	0	0	0		
Source of the Pills	Self	288	96.32	179	59.87	123.0527	<0.00001
	Pharmacist	2	0.66	98	32.78		
	Others	9	3.02	22	7.35		
How were pills packed	Blister pack	299	100	299	100		
	Loose pack	0	0	0	0		
Route of administration	sublingual	0	0	0	0	50.7076	<.00001
	Oral	67	22.4	9	3.02		
	Vaginal	232	77.6	290	96.98		
Indication of intake	unintended pregnancy	170	56.86	222	74.24		
	Life risk/ medical reason	19	6.36	0	0		
	Unmarried pregnancy	0	0	6	2		
	failure of contraception	110	36.78	71	23.74		
	Congenital anomalies	0	0	0	0		
	Others	0	0	0	0		
Interval between intake and	< 24h	41	13.71	29	9.7	2.3299	.126912
	>24h	258	86.29	270	90.3		

visit							
Chief complaint	Heavy menstrual bleeding Passage of fleshy mass	276	92.3	181	60.54		
	Irregular vaginal bleeding	15	5.02	53	17.73		
	Pain abdomen	4	1.34	24	8.03		
	Continued pregnancy	4	1.34	11	3.67		
	Pain abdomen with four smelling discharge per vaginum	0	0	30	10.03		
Outcome	Incomplete abortion	261	87.29	277	92.64		
	Complete abortion	32	10.7	9	3.01		
	Rupture ectopic	0	0	0	0		
	Missed abortion	6	2	1	0.34		
	Sepsis	0	0	9	3.01		
	Uterine perforation	0	0	1	0.34		
	Others	0	0	2	0.68		
Duration of stay	<3 days	295	98.66	274	91.63	15.9819	.000064
	>3 days	4	1.33	25	8.36		

Complications	Mild to moderate anemia	255	85.28	184	61.56		
	Severe anemia	44	14.71	74	24.76		
	Sepsis	0	0	13	4.35		
	Scar pregnancy	0	0	03	1.03		
	Mortality	0	0	5	1.62		
	Shock	0	0	7	2.34		
	Continuation of Pregnancy	0	0	13	4.34		
Management	Medical management	39	13.05	20	6.67		
	Suction & evacuation	218	72.90	114	38.13		
	S & E with blood transfusion	42	14.05	101	33.78		
	Laparotomy with blood transfusion	0	0	0	0		
	Hysterectomy with blood transfusion	0	0	2	0.67		
	Iron sucrose	0	0	55	18.39		
	Shock	0	0	7	2.36		
Awareness of MTP pills	Yes	269	89.96	250	83.61	5.2652	.021756
	No	30	10.03	49	16.38		
Awareness about other contraceptive methods	No	167	55.85	226	75.5	25.838	< .00001
	Yes	132	44.14	73	24.4		

131

132

133 Table 2: Crude and adjusted odds ratio abortion for study variables of both groups.

Characteristics		COR(95%CI)	AOR(95%CI)	
Age	<20*			
	21-30	0.91(0.68,1.22)	0.91(0.68,1.22)	
	31-40	0.87(0.71,1.10)	0.87(0.68,1.09)	
	>40	0.77(0.59,0.96)	0.71(0.55,0.91)	
Religion	Hindu*			
	Muslim	0.54(0.34,0.81)	0.51(0.32,0.74)	
Education	Literate*			
	Illiterate	0.71*(0.62,1.12)	0.71(0.65,1.09)	
Resident	Rural*			
	Urban	0.68(0.52,0.98)	0.65(0.51,0.87)	
Marital Status	Married*			
	Unmarried	0.87(0.61,1.11)	0.88(0.60,1.11)	
Economic Status	Upper*			
	Middle	0.91*(0.64,1.11)	0.89(0.61,1.02)	
	Low	0.85(0.71,1.14)	0.81(0.68,1.10)	
Medical History	Yes*			
	No	0.88(0.69,1.01)	0.85(0.61,1.01)	
Parity	G1*			
	G2	1.66***(1.41,1.92)	1.49(1.21,1.71)	
	G3	1.79***(1.14,2.71)	1.41(0.93,2.34)	
	>4*			
POG (weeks)	<9	1.33***(1.13,1.69)	1.14(0.86,1.59)	
	9-12	1.35***(1.10,1.58)	1.14(0.85,1.51)	
	>12	0.81(0.67,1.02)	0.85(0.66,1.07)	
Ascertainment of pregnancy(USG/UPT)	USG*			
	UPT	0.87(0.48,1.05)	0.88(0.51,1.06)	
No. of Pills	Complete*			
	In-complete	0.78(0.61,0.92)	0.81(0.62,1.02)	
No. of times pills were taken	Once*			
	Twice	0.66(0.51,0.89)	0.60(0.41,0.81)	
	Thrice	0.96(0.72,1.15)	1.00(0.71,1.31)	
Source of the Pills	Self*			
	Pharmacist	0.98(0.75,1.12)	0.87(0.64,1.14)	
	Others	0.74(0.51,0.89)	0.74(0.55,1.10)	
How were pills packed	Blister pack*			
	Loose pack	1.00(0.75,1.21)	0.99(0.75,1.14)	
	Route of administration	Sublingual*		
		Oral	0.87(0.74,1.10)	0.84(0.70,1.01)
	Vaginal	1.12(0.96,1.31)	1.04(0.85,1.30)	
Indication of intake	unintended pregnancy*			
	Life risk/	0.99(0.54,0.86)	1.00(0.77,1.34)	

	medical reason		
	Unmarried pregnancy	0.85(0.68,1.12)	0.81(0.75,1.10)
	failure of contraception	0.84(0.70,1.09)	0.81(0.81,1.12)
	Congenial from alone	1.22*** (0.91,1.61)	1.18(0.91,1.41)
	Others	0.81(0.68,1.01)	0.85(0.72,1.15)
Interval between intake and visit	< 24h*		
	>24h	0.92(0.65,1.12)	0.95(0.72,1.23)
	Heavy menstrual* bleeding		
	Passage of fleshy mass		
	Irregular vaginal bleeding	0.92(0.67,1.15)	0.93(0.69,1.17)
	Pain abdomen	0.82(0.68,0.99)	0.90(0.70,1.15)
	Continued pregnancy	1.08(0.87,1.31)	1.10(0.86,1.21)
	Pain abdomen with four smelling discharge per vaginum	0.98(0.77,1.19)	0.90(0.064,1.21)
Outcome	Incomplete abortion*		
	Complete abortion	1.37(1.12,1.68)	1.17(0.89,1.61)
	Rupture ectopic	1.31(1.11,1.45)	1.28(1.14,1.52)
	Missed abortion	1.22(1.24,1.46)	1.19(1.18,1.13)
	Sepsis	1.05(1.15,1.31)	1.13(1.14,1.38)
	Uterine perforation	1.12(1.14,1.32)	1.19(1.15,1.24)
	Others	1.32(1.14,1.41)	1.37(1.19,1.45)
Awareness of MTP pills	Yes*		
	No	0.98(0.62,1.10)	0.95(0.65,1.17)
Awareness about other methods	No*		
	Yes	0.83(0.69,0.99)	0.85(0.70,1.03)
Duration of stay	<3 days*		
	>3 days	0.68(0.52,0.90)	0.60(0.44,0.81)

Complications	Mild to moderate anemia*	0.85(0.78,1.06)	0.86(0.79,1.09)
	Severe anemia	0.52(0.48,0.74)	0.55(0.49,0.76)
	Sepsis	0.84(0.52,1.14)	0.87(0.55,1.12)
	Scar pregnancy	0.75(0.62,1.12)	0.77(0.68,1.05)
	Mortality	0.81(0.61,1.08)	0.81(0.65,1.01)
	Shock	0.77(0.58,0.98)	0.75(0.61,0.99)
	Continuation of Pregnancy	0.81(0.58,1.05)	0.78(0.61,1.06)
MANAGEMENT	Medical management*		
	Suction & evacuation	1.12(0.85,1.15)	1.12(0.89,1.22)
	S & E with blood transfusion	0.89(0.65,1.10)	0.85(0.61,1.17)
	Laparotomy with blood transfusion	0.92(0.81,1.12)	0.92(0.87,1.17)
	Hysterectomy c blood transfusion	0.81(0.67,1.08)	0.65(0.61,0.94)
	Iron sucrose	0.71(0.62,0.95)	0.74(0.65,0.99)
	Shock	0.66(0.57,0.81)	0.65(0.59,0.94)
Awareness of MTP pills	Yes*		
	No	0.98(0.62,1.10)	0.95(0.65,1.17)
			0.85(0.70,1.03)

134

135 Note: *Reference category; *p<0.05; ***p <0.001

136 Table: Crude and adjusted odds ratio for study variables of both groups.

137 In table the multivariate logistic regression was performed to estimate the COR and AOR of
 138 the study variables. The results shown that among the study variables, education,
 139 socioeconomic status, period of gestation and parity along with indication of intake were
 140 among the major predictors of the study.

141

142 **DISCUSSION**

143 According to WHO guidelines, medical termination of pregnancy can be safely
144 performed up to 9 weeks of gestation by a registered medical practitioner. However,
145 self-administration of medical abortion pills by unqualified individuals and lack of
146 awareness regarding the potential complications of unsupervised MTP pill intake can
147 result in severe complications such as sepsis, uterine perforation, cervical trauma,
148 and ectopic pregnancy, posing significant risks to maternal health globally.

149 This study assessed the outcomes and complications associated with supervised
150 versus unsupervised use of medical abortion pills. In the supervised group, 58.34%
151 of patients were aged 21-30 years, similar to findings by Giri et al(4). and Reema
152 Kumari et al(10)., while in the unsupervised group, 61.33% were aged 31-40 years,
153 consistent with studies by Bhalla S et al(9). Most patients belonged to the middle
154 socio-economic strata, highlighting issues such as early marriage, unplanned
155 pregnancies, career priorities, and the easy availability of MTP pills.

156 In the supervised group, all pregnancies were confirmed via ultrasound to rule out
157 ectopic pregnancies before proceeding with termination. Conversely, 90% of patients
158 in the unsupervised group used MTP pills based on urine pregnancy tests, a higher
159 rate than reported by Reema Kumari et al(10). The majority of patients in both
160 groups were from the Hindu community. In the supervised group, 72.67% of patients
161 terminated within the recommended gestational period, compared to only 28.33% in
162 the unsupervised group, which had higher termination rates at 9-12 weeks and post-
163 12 weeks gestation.

164 The unsupervised group had a higher prevalence of patients who were gravida 2,
165 followed by gravida 3 and 1, similar to findings by Reema Kumari et al(10). and
166 Singh A et al(5). In the supervised group, most patients were gravida 2. The primary
167 reason for termination in both groups was unintended pregnancy. However, studies

168 by Reema Kumari et al.⁽¹⁰⁾ and Bhalla S et al.⁽⁹⁾ indicated that privacy concerns and
169 contraception failure were also significant factors.

170 Excessive vaginal bleeding, a sign of incomplete abortion, was the main complaint in
171 92.66% of unsupervised cases, aligning with findings by Rath S et al(1)., Reema
172 Kumari et al(10)., and Bhalla S et al(9). This study revealed that 59.67% of patients
173 in the unsupervised group obtained the drugs without a prescription, underscoring
174 the widespread misuse of MTP pills despite existing sale restrictions.

175 While awareness of MTP pills was high in both groups, knowledge of alternative
176 contraceptive methods was limited. This highlights the need for enhanced education
177 on contraception and the supervised use of MTP pills to prevent complications.
178 Enforcing prescription requirements for MTP pills and implementing comprehensive
179 sex education programs are essential.

180 In the supervised group, patients were informed about potential complications and
181 the risk of ectopic pregnancy, allowing for timely medical intervention and minimizing
182 complications. Only 14% of supervised patients required surgical intervention,
183 compared to 73.67% in the unsupervised group. Blood transfusions were necessary
184 for 42% of unsupervised patients, and two required life-saving hysterectomies.
185 Complications such as shock (2.34%), sepsis (4.35%) and mortality (1.62%) had
186 been reported in this study compared to none in supervised group. Similar studies
187 were shown in the study conducted by Thakur et al(11) and Sarojini et al(13)

188 Additionally, 7 patients in unsupervised group needed laparotomy due to
189 complications like scar ectopic pregnancy and uterine perforation.

190 The study underscores the urgent need for increased awareness and strict
191 regulations regarding the use of MTP pills to reduce maternal morbidity and mortality
192 associated with unsupervised medical abortions.

193

194

195

UNDER PEER REVIEW IN IJAR

196 **CONCLUSION**

197 The current study indicates that complications are significantly higher in the
198 unsupervised group compared to the supervised group, including increased need for
199 blood transfusions, laparotomy, hysterectomy, and even maternal mortality. To
200 address this issue, it is crucial to educate and raise awareness among women at the
201 community level about family planning and the contraceptive options available at
202 hospital centres. Emphasizing the importance of taking MTP pills under medical
203 supervision is essential. Additionally, strict actions and surveillance should be
204 implemented to control the easy availability of over-the-counter pills. Addressing
205 these issues urgently is necessary to reduce the risk of women experiencing severe
206 complications or losing their lives due to unsupervised MTP pill intake.

207

208 .

209

210

UNDER PEER REVIEW

211 **REFERENCES**

- 212 1)Rath S, Mishra S, Tripathy R, Dash S, Panda B. Analysis of Complications and
213 Management After Self-Administration of Medical Termination of Pregnancy Pills.
214 Cureus. 2021 Nov 18;13(11):e19730. doi: 10.7759/cureus.19730. PMID: 34934592;
215 PMCID: PMC8684582.
- 216 2) Mahji A K (2016) Bedside clinics in obstetrics: A practical approach to theoretical
217 discussion, 4th edition, academic publishers, Kolkata(pp-575)
- 218 3)Panda, R. & Pattanaik, T. & Panigrahy, P. & Sahu, M.C.. (2016). Scenario of self
219 medication for medical abortion in a tertiary care centre. International Journal of
220 Pharmaceutical Sciences Review and Research. 39. 63-65.
- 221 4) Giri, A., Srivastav, V., Suwal, A., & Sharma, B. (2015). A Study of Complications
222 following Self-administration with Medical Abortion Pills. *Nepal Journal of Obstetrics*
223 *and Gynaecology*, 10(1), 20–24. Retrieved from
224 <https://www.nepjol.info/index.php/NJOG/article/view/13188>
- 225 5) Singh A, Bhaskaran S, SinglaA. Outcome and complications of self-administration
226 of over-the-counter abortion pills: an observational study in a tertiary care hospital of
227 a medical college in New Delhi.Int J Reprod Contracept Obstet Gynecol 2021
228 ;10:3148-52.
- 229 6) Charan J, Biswas T. How to calculate sample size for different study designs in
230 medical research? Indian J Psychol Med. 2013 Apr;35(2):121-6. doi: 10.4103/0253-
231 7176.116232. PMID: 24049221; PMCID: PMC3775042.
- 232 7) Moseson, H., Jayaweera, R., Raifman, S. *et al.* Self-managed medication abortion
233 outcomes: results from a prospective pilot study. *Reprod Health* 17, 164 (2020).
234 <https://doi.org/10.1186/s12978-020-01016-4>

- 235 8) Pradhan MR, Saikia D. Patterns and correlates of post-abortion complications in
236 India. BMC Womens Health. 2023 Mar 9;23(1):97. doi: 10.1186/s12905-023-02254-
237 x. PMID: 36894914; PMCID: PMC9998004.
- 238 7) Bhalla, Shivali & Goyal, Lajya & Bhalla, Shivam & Kaur, Balpreet. (2018). Self
239 administered medical abortion pills: evaluation of the clinical outcome and
240 complications among women presenting with unsupervised pill intake to a tertiary
241 care hospital in Malwa region of Punjab, India. International Journal of Reproduction,
242 Contraception, Obstetrics and Gynecology. 7. 1537. 10.18203/2320-
243 1770.ijrcog20181351.
- 244 10) Kumari, Reema & Tirkey, Sarita & Kumari, Archana Kumari. (2023). Over-the-
245 Counter Use of Medical Abortion Pills: A Prospective Cohort Study. Journal of
246 Clinical and Diagnostic Research. 17. 10.7860/JCDR/2023/63778.18315.
- 247 11) Nagaria, Tripti & Thakur, Neha & Verma, Ritu. (2023). Self-administration of
248 Abortion Pills and its Maternal Outcome in Tertiary Care Center. Journal of South
249 Asian Federation of Obstetrics and Gynaecology. 15. 142-146. 10.5005/jp-journals-
250 10006-2226.
- 251 12) Pourette D, Mattern C, Ratovoson R, Raharimalala P. Complications with use of
252 misoprostol for abortion in Madagascar: between ease of access and lack of
253 information. Contraception. 2018 Feb;97(2):116-121. doi:
254 10.1016/j.contraception.2017.12.005. Epub 2017 Dec 11. PMID: 29242087.
- 255 13) Sarojini, Ashakiran TR, Bhanu BT, Radhika. Over-the-counter MTP Pills and Its
256 Impact on Women's Health. J Obstet Gynaecol India. 2017 Feb;67(1):37-41. doi:
257 10.1007/s13224-016-0916-9. Epub 2016 Jun 25. PMID: 28242966; PMCID:
258 PMC5306099.
- 259

260 14) Self administration versus supervised use of Medical Abortion pills: Impact on
261 women's health. Journal of Pharmaceutical Negative Results [Internet]. 2022 Oct. 7
262 [cited 2024 Jul. 21];:475-82.

263 Available from: <https://www.pnrjournal.com/index.php/home/article/view/1716>

264 15) Bharti, Atima & Tuddu, Anjali. (2020). Study on Safety, Efficacy and
265 Complication of Medical Abortion. International Journal of Contemporary Medical
266 Research [IJCMR]. 7. 10.21276/ijcmr.2020.7.1.26.

267 16) American College of Obstetricians and Gynecologists' Committee on Practice
268 Bulletins—Gynecology, Society of Family Planning. Medication Abortion Up to 70
269 Days of Gestation: ACOG Practice Bulletin, Number 225. Obstet Gynecol. 2020
270 Oct;136(4):e31-e47. doi: 10.1097/AOG.0000000000004082. PMID: 32804884.

271

272

273

274

275

276

277

278
279
280
281
282

UNDER PEER REVIEW IN IJAR

UNDER PEER REVIEW IN IJAR